eligibility_summary
Adults ≥18, ECOG 0–2, with PET+ measurable relapsed/refractory CD20+ large B‑cell lymphoma (most subtypes, excludes Burkitt/lymphoplasmacytic). Need ≥1 prior line, SCT/CAR‑T eligible, adequate organs, life expectancy ≥6 mo, tissue available (archival ≤2y or fresh), negative pregnancy test/contraception. Exclude prior epcoritamab/BiTEs, GDP contraindication, active CNS (unless CR), recent therapy/surgery <14d, ≥G2 neuropathy, other cancers, active infections (uncontrolled HIV/HBV/HCV), pregnancy/breastfeeding, serious illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II in relapsed/refractory large B‑cell lymphoma: epcoritamab + gemcitabine/cisplatin/dexamethasone (GDP) for 3 cycles, then autologous SCT or CAR T, or epcoritamab maintenance. Interventions and mechanisms: Epcoritamab—subcutaneous bispecific IgG antibody (CD3xCD20) that redirects T cells to kill CD20+ B cells. Gemcitabine—antimetabolite nucleoside analog inhibiting ribonucleotide reductase/DNA synthesis. Cisplatin—platinum DNA crosslinker causing apoptosis. Dexamethasone—glucocorticoid, lympholytic via GR signaling. AutoSCT—high‑dose chemo with autologous stem‑cell rescue. CAR T—adoptive T‑cell therapy engineered to recognize B‑cell antigens. Targets/pathways: CD20 on malignant B cells, CD3 on T cells, DNA replication/crosslink repair, and glucocorticoid‑induced apoptosis.